PMID- 16613552
OWN - NLM
STAT- MEDLINE
DCOM- 20060522
LR  - 20191026
IS  - 1871-5273 (Print)
IS  - 1871-5273 (Linking)
VI  - 5
IP  - 1
DP  - 2006 Feb
TI  - The dopamine D3 receptor: a therapeutic target for the treatment of 
      neuropsychiatric disorders.
PG  - 25-43
AB  - The role of the D(3) receptor has remained largely elusive before the development 
      of selective research tools, such as selective radioligands, antibodies, various 
      highly specific pharmacological agents and knock-out mice. The data collected so 
      far with these tools have removed some of the uncertainties regarding the 
      functions mediated by the D(3) receptor. The D(3) receptor is an autoreceptor 
      that controls the phasic, but not tonic activity of dopamine neurons. The D(3) 
      receptor, via regulation of its expression by the brain-derived neurotrophic 
      factor (BDNF), mediates sensitization to dopamine indirect agonists. This process 
      seems responsible for side-effects of levodopa (dyskinesia) in the treatment of 
      Parkinson's disease (PD), as well as for some aspects of conditioning to drugs of 
      abuse. The D(3) receptor mediates behavioral abnormalities elicited by 
      glutamate/NMDA receptor blockade, which suggests D(3) receptor-selective 
      antagonists as novel antipsychotic drugs. These data allow us to propose novel 
      treatment options in PD, schizophrenia and drug addiction, which are awaiting 
      evaluation in clinical trials.
FAU - Sokoloff, P
AU  - Sokoloff P
AD  - INSERM, Unite de Neurobiologie et Pharmacologie, Moleculaire (U573), Centre Paul 
      Broca, 2ter rue d'Alesia, 75014 Paris, France. pierre.sokoloff@pierre-fabre.com
FAU - Diaz, J
AU  - Diaz J
FAU - Le Foll, B
AU  - Le Foll B
FAU - Guillin, O
AU  - Guillin O
FAU - Leriche, L
AU  - Leriche L
FAU - Bezard, E
AU  - Bezard E
FAU - Gross, C
AU  - Gross C
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - CNS Neurol Disord Drug Targets
JT  - CNS & neurological disorders drug targets
JID - 101269155
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Dopamine Agonists)
RN  - 0 (Dopamine Antagonists)
RN  - 0 (Receptors, Dopamine D3)
SB  - IM
MH  - Animals
MH  - Antipsychotic Agents/pharmacology
MH  - Brain/*drug effects/metabolism/physiopathology
MH  - Brain-Derived Neurotrophic Factor/metabolism
MH  - Dopamine Agonists/adverse effects
MH  - Dopamine Antagonists/pharmacology/therapeutic use
MH  - Humans
MH  - Mental Disorders/*drug therapy/metabolism/physiopathology
MH  - Neurons/*drug effects/metabolism
MH  - Receptors, Dopamine D3/*drug effects/genetics/metabolism
RF  - 239
EDAT- 2006/04/15 09:00
MHDA- 2006/05/23 09:00
CRDT- 2006/04/15 09:00
PHST- 2006/04/15 09:00 [pubmed]
PHST- 2006/05/23 09:00 [medline]
PHST- 2006/04/15 09:00 [entrez]
AID - 10.2174/187152706784111551 [doi]
PST - ppublish
SO  - CNS Neurol Disord Drug Targets. 2006 Feb;5(1):25-43. doi: 
      10.2174/187152706784111551.